Sangeeta Bhatia - Vertex Pharmaceutic Director

VRTX
 Stock
  

USD 281.79  1.44  0.51%   

  Director
Dr. Sangeeta N. Bhatia, M.D., Ph.D. is Independent Director of Vertex Pharmaceuticals Incorporated. Dr. Bhatia is a professor at the Massachusetts Institute of Technology, or MIT, where she currently serves as the John J. and Dorothy Wilson Professor of Health Sciences TechnologyElectrical Engineering Computer Science. For the 2018 year, Dr. Bhatia was on sabbatical from MIT while she served as a cofounder of Glympse Bio, a private company focused on developing in vivo sensing technology dedicated to disease monitoring. Prior to joining MIT in 2005, Dr. Bhatia was a professor of bioengineering and medicine at the University of California at San Diego from 1998 through 2005. Dr. Bhatia also is an investigator for the Howard Hughes Medical Institute, a member of the Department of Medicine at Brigham and Womens Hospital, a member of the Broad Institute and a member of the Koch Institute for Integrative Cancer Research
Age: 49  Director Since 2015  Ph.D    
617 341-6100  www.vrtx.com
Bhatia holds a Sc.B. in biomedical engineering from Brown University, an S.M. and Ph.D. in Mechanical Engineering from MIT and an M.D. from Harvard Medical School.

Sangeeta Bhatia Latest Insider Activity

Tracking and analyzing the buying and selling activities of Sangeeta Bhatia against Vertex Pharmaceutic stock is an integral part of due diligence when investing in Vertex Pharmaceutic. Sangeeta Bhatia insider activity provides valuable insight into whether Vertex Pharmaceutic is net buyers or sellers over its current business cycle. Note, Vertex Pharmaceutic insiders must abide by specific rules, including filing SEC forms every time they buy or sell Vertex Pharmaceutic'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Vertex Pharmaceutic Management Efficiency

Vertex Pharmaceutic has return on total asset (ROA) of 13.79 % which means that it generated profit of $13.79 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 24.93 %, meaning that it created $24.93 on every $100 dollars invested by stockholders. Vertex Pharmaceutic management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. Vertex Pharmaceutic Return on Investment is fairly stable at the moment as compared to the past year. Vertex Pharmaceutic reported Return on Investment of 28.05 in 2021. Return on Average Assets is likely to rise to 20.07 in 2022, whereas Return on Invested Capital is likely to drop (0.008739)  in 2022. Vertex Pharmaceutic Total Assets are fairly stable at the moment as compared to the past year. Vertex Pharmaceutic reported Total Assets of 13.43 Billion in 2021. Current Assets is likely to rise to about 10.3 B in 2022, whereas Revenue to Assets are likely to drop 0.50 in 2022.
The company currently holds 967.4 M in liabilities with Debt to Equity (D/E) ratio of 0.1, which may suggest the company is not taking enough advantage from borrowing. Vertex Pharmaceutic has a current ratio of 4.37, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Vertex Pharmaceutic until it has trouble settling it off, either with new capital or with free cash flow. So, Vertex Pharmaceutic's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Vertex Pharmaceutic sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Vertex to invest in growth at high rates of return. When we think about Vertex Pharmaceutic's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing few of many executives

DIRECTOR Since

Eric AguiarBiohaven Pharmaceutical Holding
2017
Kenneth ChenaultInternational Business Machines
2016
Kevin LoftonGilead Sciences
2009
Arthur CollinsAlcoa Corp
2015
Carol BartzCisco Systems
2005
Martha PollackInternational Business Machines
2019
Robert AlexanderAllena Pharmaceuticals
2016
James SmithPfizer Inc
2014
Dennis AusielloPfizer Inc
2015
James HughesAlcoa Corp
2016
Brian HallaCisco Systems
2007
Joan SperoInternational Business Machines
2004
James McNerneyInternational Business Machines
2009
Shirley JacksonInternational Business Machines
2005
Robert YostBank Of America
2012
Amy AlvingAlcoa Corp
2016
Steven WestCisco Systems
1996
Sidney TaurelInternational Business Machines
2001
James QuinceyPfizer Inc
2020
David FarrInternational Business Machines
2012
Robert RepellaBiohaven Pharmaceutical Holding
2018
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 00 people. Vertex Pharmaceutic (VRTX) is traded on NASDAQ Exchange in USA and employs 3,900 people.

Vertex Pharmaceutic Leadership Team

Elected by the shareholders, the Vertex Pharmaceutic's board of directors comprises two types of representatives: Vertex Pharmaceutic inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vertex. The board's role is to monitor Vertex Pharmaceutic's management team and ensure that shareholders' interests are well served. Vertex Pharmaceutic's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vertex Pharmaceutic's outside directors are responsible for providing unbiased perspectives on the board's policies.
William Young, Independent Director
Reshma Kewalramani, Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
Michael Parini, Executive Vice President and Chief Legal Officer
Alan Garber, Independent Director
Joshua Boger, Executive Director and Chairman of Science and Technology Committee
John Gray, Senior Vice President Genetic Therapies
Margaret McGlynn, Independent Director
Sangeeta Bhatia, Director
Terrence Kearney, Independent Director
Ian Smith, CFO, Executive Vice President
Paul Silva, Senior Vice President Corporate Controller
David Altshuler, Independent Director
Jeffrey Chodakewitz, Chief Medical Officer and Senior Vice President - Global Medicines Development
Elaine Ullian, Co-Lead Independent Director
Amit Sachdev, Senior Vice President - Global Government Strategy, Market Access and Value
David Greenway, Director
Charles Wagner, CFO, Executive Vice President
Bruce Sachs, Co-Lead Independent Director
Lloyd Carney, Independent Director
Michael Partridge, Vice President - Investor Relations
Yuchun Lee, Independent Director
Kimberly White, Senior Vice President and Chief Communications Officer
Stuart Arbuckle, Chief Commercial Officer and Executive VP
Thomas Graney, CFO, Senior Vice President
Charles Milstein, Executive Vice President Chief Legal and Administrative Officer
Jeffrey Leiden, Chairman of the Board and Presidentident, CEO

Vertex Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vertex Pharmaceutic a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Vertex Pharmaceutic without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Bond Analysis Now

   

Bond Analysis

Evaluate and analyze corporate bonds as a potential investment for your portfolios.
All  Next Launch Module

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Also, please take a look at World Market Map. Note that the Vertex Pharmaceutic information on this page should be used as a complementary analysis to other Vertex Pharmaceutic's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Complementary Tools for Vertex Stock analysis

When running Vertex Pharmaceutic price analysis, check to measure Vertex Pharmaceutic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceutic is operating at the current time. Most of Vertex Pharmaceutic's value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceutic's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Vertex Pharmaceutic's price. Additionally, you may evaluate how the addition of Vertex Pharmaceutic to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Is Vertex Pharmaceutic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vertex Pharmaceutic. If investors know Vertex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vertex Pharmaceutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
0.19
Market Capitalization
70.6 B
Quarterly Revenue Growth YOY
0.22
Return On Assets
0.14
Return On Equity
0.25
The market value of Vertex Pharmaceutic is measured differently than its book value, which is the value of Vertex that is recorded on the company's balance sheet. Investors also form their own opinion of Vertex Pharmaceutic's value that differs from its market value or its book value, called intrinsic value, which is Vertex Pharmaceutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vertex Pharmaceutic's market value can be influenced by many factors that don't directly affect Vertex Pharmaceutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vertex Pharmaceutic's value and its price as these two are different measures arrived at by different means. Investors typically determine Vertex Pharmaceutic value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vertex Pharmaceutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.